Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis

M. Schneiderova, A. Naccarati, B. Pardini, F. Rosa, CD. Gaetano, K. Jiraskova, A. Opattova, M. Levy, K. Veskrna, V. Veskrnova, T. Buchler, S. Landi, P. Vodicka, V. Vymetalkova,

. 2017 ; 32 (5) : 533-542.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18033648

Grant support
NT13424 MZ0 CEP Register
NV15-27580A MZ0 CEP Register

According to the Vogelstein's model of colorectal carcinogenesis, genetic variations in highly penetrant genes may be involved in the colorectal cancer (CRC) pathogenesis. Similarly, aberrant function and/or altered expression of microRNAs (miRNAs) often occur in CRC. In this context, polymorphisms in miRNA-binding sites (miRSNPs) may affect miRNA/target gene interaction, resulting in differential mRNA/protein expression and increased susceptibility to common diseases. To explore this phenomenon, we have mined the 3' untranslated regions (3'UTRs) of genes known to be frequently mutated in CRC to search for miRSNPs and tested their association with CRC risk and clinical outcome. Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls). The role of these miRSNPs was also investigated in relation to clinical outcome on a subset of patients with complete follow-up. rs8679 within PARP1 was associated with CRC risk and patients' survival. In the dominant model, carriers of at least one C allele were at a decreased risk of cancer (P = 0.05). The CC genotype in rs8679 was also associated with an increased risk of recurrence/progression in patients that received 5-FU-based chemotherapy (log-rank test P = 0.03). Carriers of the homozygous variant genotype TT for rs712 in KRAS gene were associated with a decreased risk of rectal cancer (odds ratio (OR) = 0.65, 95% confidence intervals (CI) 0.43-1.00, P = 0.05) while individuals with colon cancer carrying the heterozygous GT genotype showed a longer overall survival (OS) (P = 0.04). We provide the first evidence that variations in potential miRNA-binding target sites in the 3' UTR of PARP1 gene may modulate CRC risk and prognosis after therapy. Further studies are needed to replicate our finding and assess miRSNPs as predictive biomarkers in independent populations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033648
003      
CZ-PrNML
005      
20181113113942.0
007      
ta
008      
181008s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/mutage/gex026 $2 doi
035    __
$a (PubMed)29048575
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schneiderová, Michaela $u Department of Surgery, General University Hospital in Prague, Prague 12800, Czech Republic. $7 xx0239518
245    10
$a MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis / $c M. Schneiderova, A. Naccarati, B. Pardini, F. Rosa, CD. Gaetano, K. Jiraskova, A. Opattova, M. Levy, K. Veskrna, V. Veskrnova, T. Buchler, S. Landi, P. Vodicka, V. Vymetalkova,
520    9_
$a According to the Vogelstein's model of colorectal carcinogenesis, genetic variations in highly penetrant genes may be involved in the colorectal cancer (CRC) pathogenesis. Similarly, aberrant function and/or altered expression of microRNAs (miRNAs) often occur in CRC. In this context, polymorphisms in miRNA-binding sites (miRSNPs) may affect miRNA/target gene interaction, resulting in differential mRNA/protein expression and increased susceptibility to common diseases. To explore this phenomenon, we have mined the 3' untranslated regions (3'UTRs) of genes known to be frequently mutated in CRC to search for miRSNPs and tested their association with CRC risk and clinical outcome. Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls). The role of these miRSNPs was also investigated in relation to clinical outcome on a subset of patients with complete follow-up. rs8679 within PARP1 was associated with CRC risk and patients' survival. In the dominant model, carriers of at least one C allele were at a decreased risk of cancer (P = 0.05). The CC genotype in rs8679 was also associated with an increased risk of recurrence/progression in patients that received 5-FU-based chemotherapy (log-rank test P = 0.03). Carriers of the homozygous variant genotype TT for rs712 in KRAS gene were associated with a decreased risk of rectal cancer (odds ratio (OR) = 0.65, 95% confidence intervals (CI) 0.43-1.00, P = 0.05) while individuals with colon cancer carrying the heterozygous GT genotype showed a longer overall survival (OS) (P = 0.04). We provide the first evidence that variations in potential miRNA-binding target sites in the 3' UTR of PARP1 gene may modulate CRC risk and prognosis after therapy. Further studies are needed to replicate our finding and assess miRSNPs as predictive biomarkers in independent populations.
650    12
$a 3' nepřekládaná oblast $7 D020413
650    _2
$a protein familiární adenomatózní polypózy $x genetika $7 D025601
650    _2
$a senioři $7 D000368
650    _2
$a protinádorové antimetabolity $x terapeutické užití $7 D000964
650    _2
$a ATM protein $x genetika $7 D064007
650    _2
$a vazebná místa $7 D001665
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kolorektální nádory $x farmakoterapie $x genetika $x metabolismus $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoruracil $x terapeutické užití $7 D005472
650    12
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x metabolismus $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a poly(ADP-ribosa)polymerasa 1 $x genetika $x metabolismus $7 D000071137
650    12
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny p21(ras) $x genetika $7 D016283
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a protein Smad7 $x genetika $7 D051906
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Naccarati, Alessio $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic. Molecular and Genetic Epidemiology; Genomic Variation in Human Populations and Complex Diseases, IIGM Italian Institute for Genomic Medicine, Via Nizza 52, 10126 Turin, Italy.
700    1_
$a Pardini, Barbara $u Molecular and Genetic Epidemiology; Genomic Variation in Human Populations and Complex Diseases, IIGM Italian Institute for Genomic Medicine, Via Nizza 52, 10126 Turin, Italy. $7 _AN058834
700    1_
$a Rosa, Fabio $u Molecular and Genetic Epidemiology; Genomic Variation in Human Populations and Complex Diseases, IIGM Italian Institute for Genomic Medicine, Via Nizza 52, 10126 Turin, Italy.
700    1_
$a Gaetano, Cornelia Di $u Molecular and Genetic Epidemiology; Genomic Variation in Human Populations and Complex Diseases, IIGM Italian Institute for Genomic Medicine, Via Nizza 52, 10126 Turin, Italy. Department of Medical Sciences, University of Turin, Via Verdi 8, 10124 Turin, Italy.
700    1_
$a Jiraskova, Katerina $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic. Institute of Biology Medicine Genet., First Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08 Prague, Czech Republic.
700    1_
$a Opattova, Alena $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic. Institute of Biology Medicine Genet., First Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08 Prague, Czech Republic.
700    1_
$a Levý, Miroslav $u Department of Surgery, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic. $7 xx0198664
700    1_
$a Veskrna, Karel $u Department of Surgery, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic.
700    1_
$a Veskrnova, Veronika $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic.
700    1_
$a Landi, Stefano $u Department of Biology, University of Pisa, Via Derna 1, 56126 Pisa, Italy.
700    1_
$a Vodička, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic. Institute of Biology Medicine Genet., First Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08 Prague, Czech Republic. $7 xx0060269
700    1_
$a Vymetálková, Veronika $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic. Institute of Biology Medicine Genet., First Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08 Prague, Czech Republic. $7 xx0102721
773    0_
$w MED00003429 $t Mutagenesis $x 1464-3804 $g Roč. 32, č. 5 (2017), s. 533-542
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29048575 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181113114027 $b ABA008
999    __
$a ok $b bmc $g 1340235 $s 1030642
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 32 $c 5 $d 533-542 $i 1464-3804 $m Mutagenesis $n Mutagenesis $x MED00003429
GRA    __
$a NT13424 $p MZ0
GRA    __
$a NV15-27580A $p MZ0
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options